Clinical Trial Update: Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating peri-operative treatment of resectable gastroesophageal cancer with bemarituzumab (BEMA) plus perioperative therapy; recruitment…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Cancer

Drugs mentioned

• Bemarituzumab (bemarituzumab)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: GastroEsophageal Cancer | Phase 1 | Status: NOT_YET_RECRUITING